News | May 12, 2023
Gilead acquires XinThera to strengthen pipeline in oncology
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
Acquisition of XinThera provides Gilead with precision small molecules focused on PARP1 and MK2 Inhibitors
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Bridging the gap between histopathology and molecular pathology
China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
This was a pre-approval inspection to cover our Oncology Injectable drug products for which ANDAs were filed with USFDA
This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Subscribe To Our Newsletter & Stay Updated
